Background Recent clinical trials have evaluated the efficacy of vonoprazan‐amoxicillin
(VA) dual therapy as the first‐line treatment for Helicobacter pylori infection in different …

Despite the declining trend of Helicobacter pylori (H. pylori) prevalence around the globe,
ongoing efforts are still needed to optimize current and future regimens in view of the …

Introduction: Vonoprazan, a novel potassium-competitive acid blocker, has a strong acid
suppression effect and potent efficacy in acid-associated diseases, including Helicobacter …

The eradication of Helicobacter pylori (H. pylori) infection remains challenging due to
increasing bacterial resistance. Resistance rates to clarithromycin, metronidazole, and …

Aim To evaluate the efficacy and safety of vonoprazan–amoxicillin (VA) dual therapy for
radically eradicating Helicobacter pylori (H. pylori). Methods The PubMed, Cochrane …

Background: Vonoprazan, a novel acid-suppressive drug, is non-inferior to proton pump
inhibitors (PPIs) for the management of gastric acid-related diseases. However, the safety of …

Purpose Vonoprazan (VPZ), a reversible H+–K+ ATPase inhibitor, has a relatively fast and
sustained acid-suppression action that is unaffected by diet or gene polymorphisms. Several …

Objectives: To describe the pharmacology, efficacy, safety, and potential role of vonoprazan
with amoxicillin or amoxicillin and clarithromycin for the treatment of Helicobacter pylori …

Background The amoxicillin dose used in dual therapy to eradicate Helicobacter pylori
varies across studies and the optimal amoxicillin dose for vonoprazan‐based dual therapies …

Bismuth-containing quadruple therapy (BQT) has long been recommended for Helicobacter
pylori (H. pylori) eradication in China. Meanwhile, in the latest national consensus in China …